PREMYOM - 2024 kick-off meeting
The PREMYOM project kick-off meeting took place in July in Paris, hosted by the project coordinator EssilorLuxottica at its Center for Innovation and Technologies (CI&T).View more
PREMYOM Project is starting!
We are proud to announce the launch of the PREMYOM (Prise en charge et Ralentissement de la MYopie par l’Optique Médicale) project!View more
Abstract
The PREMYOM project (Prise en charge et Ralentissement de l’Epidémie de MYopie par l’Optique Médicale), focused on medical optics-based solutions to slow down the global myopia epidemic, aims to establish the Gold Standard for personalized myopia treatment through rigorous investigation, development, and delivery.
PREMYOM is a multidisciplinary consortium of well-known partners from industry, healthcare and research, coordinated by EssilorLuxottica, bringing an unprecedented blend of technical, clinical, and digital expertise: Hôpital Fondation Adolphe de Rothschild, Institut Français de Myopie, Inria, InSimo, Institut Mines-Télécom, and Institut de la Vision.
The project has been selected for co-funding by the French Prime Minister's Secrétariat Général Pour l’Investissement (SGPI) and its operating agency Bpifrance as part of the France 2030 plan and i-Demo-2 State funding, highlighting the critical importance of addressing children's visual health as a major public health issue and tackling European myopia epidemic.
Objectives
Myopia is a growing public health threat. By 2050, approx. 4.7 billion people, i.e. more than 50% of the world’s population is expected to suffer from myopia, up from 2.8 billion today. It affects vision quality, increases the risk of eye diseases such as glaucoma or retina delamination, and reduces quality of life. Up to one billion people will be high myopes (superior to -5 Diopters) by 2050, risking blindness.
Current myopia control solutions are not personalized and do not address the individual underlying causes of myopia progression.
PREMYOM aims to bring myopia management in a new personalization era by investigating both the clinical and biological factors of myopia progression and developing innovative ophthalmic solutions that are tailored to each individual's needs and preferences.
This project has been funded by the French government as part of France 2030.
EssilorLuxottica
[ EssilorLuxottica ]
France
Thierry VILLETTE
Thierry VILLETTE
Project coordinator
InSimo
[ InSimo ]
France
Thomas JUND
Thomas JUND
Director of Ophthalmic Simulation
Hôpital Fondation Adolphe de Rothschild
[ HFAR ]
France
Jeanne Fabiola GABA
Jeanne Fabiola GABA
Inria
[ Inria ]
France
Morgane GILG
Morgane GILG
Project Manager
Fondation Voir et Entendre - Institut de la Vision
[ FVE - IdV ]
France
Agathe LARMOR
Agathe LARMOR
Institut Mines Télécom
[ IMT ]
France
Stéphane RENOUARD
Stéphane RENOUARD
graph - chart
news
.jpg)
events
Kick off meeting